Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?

The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's intention to lower drug prices and slap a tariff on pharma imports. These two efforts could weigh significantly on these companies' earnings -- and uncertainty about when and how they would be rolled out prompted investors to think twice about buying shares of drugmakers.This week, though, one company in particular took a step to remove the uncertainty. Pfizer (NYSE: PFE) became the first drugmaker to strike a deal with Trump on pricing, and in return won exemption from import tariffs for three years. Shares of the pharma giant took off, rising 14% in two trading sessions.Considering this landmark drug pricing agreement with the president, is Pfizer stock a buy? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool